Citations

Clear

4093 citation(s) found for "Yu, Jonathan".

NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019
Armstrong, Deborah K. , Alvarez, Ronald D. , Barroilhet, Lisa , Berek, Jonathan S. , Cristea, Mihaela , DeRosa, Marie, ElNaggar, Adam C. , Gray, Heidi J. , Hakam, Ardeshir, Jain, Angela, Liu, Joyce F. , Mahdi, Haider , Matei, Daniela , McHale, Michael , O’Malley, David M. , Penson, Richard T. , Percac‐Lima, Sanja , Ratner, Elena , Remmenga, Steven W., Sabbatini, Paul , Werner, Theresa L. , Zsíros, Emese , Burns, Jennifer L. , Engh, Anita M. , Matei, Daniela E , O'Malley, David M , Bakkum‐Gamez, Jamie N. , Behbakht, Kian , Berchuck, Andrew , Chen, Lee-may , Gershenson, David M. , Johnston, Carolyn , Leath, Charles A , McLean, Karen

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 7, 2019 | Volume: 17 | Issue: 8 | Pages: 896-909

10.6004/jnccn.2019.0039 | PMID 31390583 Get It

Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States, with less than half of patients living >5 years from diagnosis. A major challenge in treating ovarian cancer is that most patients have advanced disease at initial diagnosis. The best outcomes are observed in patients whose primary treatment includes complete resection of all visible disease plus combination platinum-based chemotherapy. Research efforts are focused on primary neoadjuvant treatments that may improve resectability, as well as systemic therapies providing improved long-term survival. These NCCN Guidelines Insights focus on recent updates to neoadjuvant chemotherapy recommendations, including the addition of hyperthermic intraperitoneal chemotherapy, and the role of PARP inhibitors and bevacizumab as maintenance therapy options in select patients who have completed primary chemotherapy.
Correlation Between Kappa Prozone Effect and IgA Kappa M Proteins in Serum Free Light-Chain Assay
Turner, Katherine A., Eckelkamp, Laura L, Kalass, Stephanie, Martinez, Mark, Brewer, Hayley R, Hoyne, Jonathan , Snyder, Melissa R. , Murray, David , Kalass, Stephanie J, Martinez, Mark A, Hoyne, Jonathan B, Murray, David L., Willrich, Maria A V, Martinez, Mark A, Willrich, Maria Alice V.

Mayo Clinic

Clinical Chemistry | August 6, 2019 | Volume: 65 | Issue: 10 | Pages: 1327-1329

10.1373/clinchem.2019.306456 | PMID 31387883 Get It

Three-Dimensional Printing: Current Use in Rhinology and Endoscopic Skull Base Surgery
Low, Christopher M. , Matsumoto, Jane S., Stokken, Janalee K., O’Brien, Erin K. , O'Brien, Erin K., O'Brien, Erin K , Morris, Jonathan M. , Price, Daniel L. , Matsumoto, Jane M., Choby, Garret

Mayo Clinic

American Journal of Rhinology & Allergy | August 5, 2019 | Volume: 33 | Issue: 6 | Pages: 770-781

10.1177/1945892419866319 | PMID 31382761 Get It

Background In the discipline of rhinology and endoscopic skull base surgery (ESBS), 3-dimensional (3D) printing has found meaningful application in areas including preoperative surgical planning as well as in surgical education. However, its scope of use may be limited due to the perception among surgeons that there exists a prohibitively high initial investment in resources and time to acquire the requisite technical expertise. Nevertheless, given the ever decreasing cost of advancing technology coupled with the need to understand the complex spatial relationships of the paranasal sinuses and skull base, the use of 3D printing in rhinology and ESBS is poised to blossom. Objective Help the reader identify current or potential future uses of 3D printing technology relevant to their rhinologic clinical or educational practice. Methods A review of published literature relating to 3D printing in rhinology and ESBS was performed. Results Results were reviewed and organized into 5 overarching categories including an overview of the 3D printing process as well as applications of 3D printing including (1) surgical planning, (2) custom prosthetics and implants, (3) patient education, and (4) surgical teaching and assessment. Conclusion In the discipline of rhinology and ESBS, 3D printing finds use in the areas of presurgical planning, patient education, prosthesis creation, and trainee education. As this technology moves forward, these products will be more broadly available to providers in the clinical and educational setting. The possible applications are vast and have great potential to positively impact surgical training, patient satisfaction, and most importantly, patient outcomes.
A four‐gene transcript score to predict metastatic‐lethal progression in men treated for localized prostate cancer: Development and validation studies
Cheng, Anqi , Zhao, Shanshan , Wright, Jonathan L. , Kolb, Suzanne , Karnes, R. Jeffrey , Jenkins, Robert B. , Ostrander, Elaine A. , Feng, Ziding , Fan, Jian‐Bing , Dai, James Y. , Stanford, Janet L. , Stanford, Janet L , Dai, James Y , FitzGerald, Liesel M. , Davicioni, Elai

Mayo Clinic

The Prostate | August 3, 2019 | Volume: 79 | Issue: 14 | Pages: 1589-1596

10.1002/pros.23882 | PMID 31376183 Get It

AbstractBackgroundMolecular studies have tried to address the unmet need for prognostic biomarkers in prostate cancer (PCa). Some gene expression tests improve upon clinical factors for prediction of outcomes, but additional tools for accurate prediction of tumor aggressiveness are needed.MethodsBased on a previously published panel of 23 gene transcripts that distinguished patients with metastatic progression, we constructed a prediction model using independent training and testing datasets. Using the validated messenger RNAs and Gleason score (GS), we performed model selection in the training set to define a final locked model to classify patients who developed metastatic‐lethal events from those who remained recurrence‐free. In an independent testing dataset, we compared our locked model to established clinical prognostic factors and utilized Kaplan‐Meier curves and receiver operating characteristic analyses to evaluate the model's performance.ResultsThirteen of 23 previously identified gene transcripts that stratified patients with aggressive PCa were validated in the training dataset. These biomarkers plus GS were used to develop a four‐gene (CST2, FBLN1, TNFRSF19, and ZNF704) transcript (4GT) score that was significantly higher in patients who progressed to metastatic‐lethal events compared to those without recurrence in the testing dataset (P = 5.7 × 10−11). The 4GT score provided higher prediction accuracy (area under the ROC curve [AUC] = 0.76; 95% confidence interval [CI] = 0.69‐0.83; partial area under the ROC curve [pAUC] = 0.008) than GS alone (AUC = 0.63; 95% CI = 0.56‐0.70; pAUC = 0.002), and it improved risk stratification in subgroups defined by a combination of clinicopathological features (ie, Cancer of the Prostate Risk Assessment‐Surgery).ConclusionOur validated 4GT score has prognostic value for metastatic‐lethal progression in men treated for localized PCa and warrants further evaluation for its clinical utility.
Rates of lobar atrophy in asymptomatic MAPT mutation carriers
Senjem, Matthew L. , Tosakulwong, Nirubol , Lesnick, Timothy G. , Brushaber, Danielle , Dheel, Christina, Fields, Julie A. , Forsberg, Leah K. , Gavrilova, Ralitza H. , Gearhart, Debra, Graff‐Radford, Jonathan, Graff‐Radford, Neill R., Jack, Clifford R. , Kremers, Walter K. , Rademakers, Rosa , Syrjanen, Jeremy A. , Boxer, Adam L. , Rosen, Howie, Kantarci, Kejal , Senjem, Matthew, Jack, Clifford R , Senjem, Matthew L , Kantarci, Kejal , Kremers, Walter K , Chen, Qin , Boeve, Bradley F. , Graff‐Radford, Jonathan , Graff‐Radford, Neill R. , Jones, David T. , Knopman, David S. , Lapid, Maria I. , Wszołek, Zbigniew K.

Mayo Clinic

Alzheimer's & Dementia: Translational Research & Clinical Interventions | July 30, 2019 | Volume: 5 | Issue: 1 | Pages: 338-346

10.1016/j.trci.2019.05.010 | PMID 31388560 Get It

Abstract Introduction The aim of this study was to investigate the rates of lobar atrophy in the asymptomatic microtubule‐associated protein tau ( MAPT ) mutation carriers. Methods MAPT mutation carriers (n = 14; 10 asymptomatic, 4 converters from asymptomatic to symptomatic) and noncarriers (n = 13) underwent structural magnetic resonance imaging and were followed annually with a median of 9.2 years. Longitudinal changes in lobar atrophy were analyzed using the tensor‐based morphometry with symmetric normalization algorithm. Results The rate of temporal lobe atrophy in asymptomatic MAPT mutation carriers was faster than that in noncarriers. Although the greatest rate of atrophy was observed in the temporal lobe in converters, they also had increased atrophy rates in the frontal and parietal lobes compared to noncarriers. Discussion Accelerated decline in temporal lobe volume occurs in asymptomatic MAPT mutation carriers followed by the frontal and parietal lobe in those who have become symptomatic. The findings have implications for monitoring the progression of neurodegeneration during clinical trials in asymptomatic MAPT mutation carriers.
Association between the Charlson comorbidity index and outcomes after implantable cardioverter defibrillator generator replacement
Amin, Mustapha M., Witt, Chance M. , Waks, Jonathan W. , Mehta, Ramila A. , Friedman, Paul A. , Kramer, Daniel B. , Buxton, Alfred E. , Mulpuru, Siva K. , Hodge, David O. , Frey, Rebecca J., Frederick, Nicolette K., Cha, Yong‐Mei , Brenes-Salazar, Jorge A., Madhavan, Malini , Brenes-Salazar, Jorge

Mayo Clinic

Pacing and Clinical Electrophysiology | July 29, 2019 | Volume: 42 | Issue: 9 | Pages: 1236-1242

10.1111/pace.13762 | PMID 31355952 Get It

AbstractBackgroundRecipients of implantable cardioverter defibrillator (ICD) generator replacement with multiple medical comorbidities may be at higher risk of adverse outcomes that attenuate the benefit of ICD replacement. The aim of this investigation was to study the association between the Charlson comorbidity index (CCI) and outcomes after ICD generator replacement.MethodsAll patients undergoing first ICD generator replacement at Mayo Clinic, Rochester and Beth Israel Deaconess Medical Center, Boston between 2001 and 2011 were identified. Outcomes included: (a) all‐cause mortality, (b) appropriate ICD therapy, and (c) death prior to appropriate therapy. Multivariable Cox regression analysis was performed to assess association between CCI and outcomes.ResultsWe identified 1421 patients with mean age of 69.6 ± 12.1 years, 81% male and median (range) CCI of 3 (0‐18). During a mean follow‐up of 3.9 ± 3 years, 52% of patients died, 30.6% experienced an appropriate therapy, and 23.6% died without experiencing an appropriate therapy. In multivariable analysis, higher CCI score was associated with increased all‐cause mortality (Hazard ratio, HR 1.10 [1.06‐1.13] per 1 point increase in CCI, P < .001), death without prior appropriate therapy (HR 1.11 [1.07‐1.15], P < .0001), but not associated with appropriate therapy (HR 1.01 [0.97‐1.05], P = .53). Patients with CCI ≥5 had an annual risk of death of 12.2% compared to 8.7% annual rate of appropriate therapy.ConclusionsCCI is predictive of mortality following ICD generator replacement. The benefit of ICD replacement in patients with CCI score ≥5 should be investigated in prospective studies.
Relationships between the use of pharmacomechanical catheter-directed thrombolysis, sonographic findings, and clinical outcomes in patients with acute proximal DVT: Results from the ATTRACT Multicenter Randomized Trial
Weinberg, Ido , Salter, Amber , Hadley, Gail, Al‐Hammadi, Noor , Kearon, Clive, Julian, Jim A. , Gornik, Heather L. , Goldhaber, Samuel Z. , Comerota, Anthony J. , Kindzelski, Andrei, Schainfeld, Robert M. , Angle, John F. , Misra, Sanjay , Schor, Jonathan , Hurst, Darren, Investigators, for the ATTRACT Trial, Gornik, Heather L , Misra, Sanjay , Vedantham, Suresh , Razavi, Mahmood K. , Jaff, Michael R. , Investigators, for the ATTRACT Trial

Mayo Clinic

Vascular Medicine | July 27, 2019 | Volume: 24 | Issue: 5 | Pages: 442-451

10.1177/1358863x19862043 | PMID 31354089 Get It

Few studies have documented relationships between endovascular therapy, duplex ultrasonography (DUS), post-thrombotic syndrome (PTS), and quality of life (QOL). The Acute Venous Thrombosis: Thrombus Removal with Adjunctive Catheter-Directed Thrombolysis (ATTRACT) trial randomized 692 patients with acute proximal deep vein thrombosis (DVT) to receive anticoagulation or anticoagulation plus pharmacomechanical catheter-directed thrombolysis (PCDT). Compression DUS was obtained at baseline, 1 month and 12 months. Reflux DUS was obtained at 12 months in a subset of 126 patients. Clinical outcomes were collected over 24 months. At 1 month, patients who received PCDT had less residual thrombus compared to Control patients, evidenced by non-compressible common femoral vein (CFV) (21% vs 35%, p < 0.0001), femoral vein (51% vs 70%, p < 0.0001), and popliteal vein (61% vs 74%, p < 0.0001). At 12 months, in the ultrasound substudy, valvular reflux prevalence was similar between groups (85% vs 91%, p = 0.35). CFV non-compressibility at 1 month was associated with higher rates of any PTS (61% vs 46%, p < 0.001), a higher incidence of moderate-or-severe PTS (30% vs 19%, p = 0.003), and worse QOL (difference 8.2 VEINES-QOL (VEnous INsufficiency Epidemiological and Economic Study on Quality of Life) points; p = 0.004) at 24 months. Valvular reflux at 12 months was associated with moderate-or-severe PTS at 24 months (30% vs 0%, p = 0.01). In summary, PCDT results in less residual thrombus but does not reduce venous valvular reflux. CFV non-compressibility at 1 month is associated with more PTS, more severe PTS, and worse QOL at 24 months. Valvular reflux may predispose to moderate-or-severe PTS. ClinicalTrials.gov Identifier NCT00790335.
CSF Pressure, Volume, and Post‐Dural Puncture Headache: A Case‐Control Study and Systematic Review
Grory, Brian Mac , Butterfield, Richard , Khokar, Babar, Falk, Bryce L., Marks, Lisa , Butterfield, Richard J, Marks, Lisa A., Marks, Lisa A , Smith, Jonathan H. , Mac Grory, Brian

Mayo Clinic

Headache: The Journal of Head and Face Pain | July 25, 2019 | Volume: 59 | Issue: 8 | Pages: 1324-1338

10.1111/head.13602 | PMID 31342523 Get It

Objectives (1) To perform a systematic literature review to evaluate associations between post‐dural puncture headache (PDPH) and opening pressure (OP), closing pressure (CP), and volume of cerebrospinal fluid (V) removed. (2) To perform a case‐control study to evaluate pressure‐volume index (PVI) as a novel risk factor for PDPH. Background According to the International Classification of Headache Diagnoses, 3rd Edition (ICHD‐3), the diagnosis of PDPH requires documentation of intracranial hypotension. However, this remains an unproven concept. Methods A systematic literature review was conducted, searching Cochrane Database of Systematic Reviews, Ovid EMBASE, OVID MEDLINE, Scopus, and Web of Science. Study inclusion required a comparison of headache incidence following a LP as a function of OP, CP, and/or V. A retrospective, case‐control study with 1:1 matching was conducted utilizing ICHD‐3 criteria. Patients with factors that could influence CSF pressure were excluded. Results In our case‐control study, we did not identify a paired difference in either median (95% CI) elastance (0.05 [−0.09, 0.11], P = .503) or PVI (4.53 [−7.98, 19.97], P = .678). We identified 22 references, evaluating V (n = 14), OP (n = 11), and/or CP (n = 4). There was no convincing evidence for an association of PDPH with either OP or CP. A minority of studies documenting an association with V included patients with high‐volume CSF removal, and/or stratified patients by the timing of the headache onset. Conclusions The overall risk of PDPH does not appear to be influenced by OP, CP, V or PVI. PDPH may be related to V in instances of high‐volume removal, and depend on the timing of outcome assessment. Future revision of criteria should consider the existence of immediate and delayed PDPH subtypes, and not presume intracranial hypotension as a mandatory feature.
An Anatomic and Clinical Study of the Innervation of the Dorsal Midfoot Capsule
Shi, Glenn G. , Williams, Meredith, Whalen, Joseph L., Wilke, Benjamin K. , Kraus, Jonathan C. , Williams, Meredith A, Wilke, B K , Shi, Glenn G

Mayo Clinic

Foot & Ankle International | July 23, 2019 | Volume: 40 | Issue: 10 | Pages: 1209-1213

10.1177/1071100719858143 | PMID 31331190 Get It

Background: Dorsal pain from osteoarthritic midfoot joints is thought to be relayed by branches of the medial and lateral plantar, sural, saphenous, and deep peroneal nerves (DPN). However, there is no consensus on the actual number or pathways of the nervous branches for midfoot joint capsular innervation. This study examined the DPN’s terminal branches at the midfoot joint capsules through anatomic dissection and confirmation of their significance in a clinical case series of patients with midfoot pain relief after DPN block. Methods: Eleven cadaveric lower leg specimens, 6 left and 5 right, were dissected using operative loupe magnification. We preserved the terminal branches and recorded their paths and branching patterns. Joint capsular innervations were individually noted. To confirm our hypothesis of significant dorsal midfoot joint capsular innervation by the DPN, we also performed an institutional review board–approved retrospective chart review of 37 patients with painful dorsal midfoot osteoarthritis who underwent diagnostic local anesthetic injection block of the DPN. The percentage of temporary pain relief after the injection was recorded. Results: Terminal innervation of the DPN branches showed distribution of the second and third tarsometatarsal joints in all specimens. Inconsistent innervation of the naviculocuneiform (9/11), fourth (7/11), first (6/11), and fifth (4/11) tarsometatarsal and calcaneocuboid joints (1/11) were observed. The retrospective review of pain relief in patients with dorsal midfoot pain due to arthritis after diagnostic injection demonstrated a mean of 92.1% improvement. Conclusion: Innervation of the dorsal midfoot joint capsule appears to follow a consistent distribution across 3 joints: second and third tarsometatarsal joints and the naviculocuneiform joint. Acute relief of dorsal midfoot arthritic pain after diagnostic injection suggests that dorsal midfoot nociceptive pain is at least partly transmitted by the DPN. Level of Evidence: Level IV, case series.
Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma
Stephens, Deborah M. , Li, Hongli , Straus, David J. , Moskowitz, Craig H. , Bartlett, Nancy L. , Evens, Andrew M. , LaCasce, Ann S. , Knopp, Michael V. , Leonard, John P. , Smith, Sonali M. , Friedberg, Jonathan W. , Bartlett, Nancy L , Evens, Andrew M , Stephens, Deborah M , Schöder, Heiko , LeBlanc, Michael , Rimsza, Lisa M. , Barr, Paul M. , Hsi, Eric D. , Kahl, Brad S.

Mayo Clinic

Blood | July 23, 2019 | Volume: 134 | Issue: 15 | Pages: 1238-1246

10.1182/blood.2019000719 | PMID 31331918 Get It

AbstractThe investigators present results on the long-term value and limitations of early interim positron emission tomography (PET) scanning in advanced Hodgkin lymphoma.